Approval · Notice of Compliance 13730 · 2012
POTIGA: Notice of Compliance 13730
Issued October 18, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13730
- Date
- October 18, 2012
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Antiepileptic Agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| POTIGA | 02394944 | — |
| POTIGA | 02394960 | — |
| POTIGA | 02394979 | — |
| POTIGA | 02394987 | — |
| POTIGA | 02394995 | — |
Medicinal ingredients
- RETIGABINE 50 MG per TAB
- RETIGABINE 100 MG per TAB
- RETIGABINE 200 MG per TAB
- RETIGABINE 300 MG per TAB
- RETIGABINE 400 MG per TAB